Inactive Instrument

News Regulus Therapeutics Inc Nasdaq

Equities

US75915K1016

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Regulus: Q4 Earnings Snapshot	Mar. 21	AQ
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates	Mar. 21	PR
Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Canaccord Genuity Trims Price Target on Regulus Therapeutics to $11 From $12, Maintains Buy Rating	Mar. 19	MT
Leerink Partners Initiates Regulus Therapeutics at Outperform Rating With $6 Price Target	Mar. 18	MT
Emerging Companies: Key Developments and Investment Insights RGLS, INBS, VTAK, DYAI, TCBP	Mar. 14	AQ
Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors	Mar. 13	CI
Wells Fargo Adjusts Regulus Therapeutics Price Target to $3 From $2, Maintains Equal Weight Rating	Mar. 13	MT
Top Midday Gainers	Mar. 12	MT
Regulus Therapeutics Reports 'Positive' Data From Second Cohort of Kidney Disease Trial -- Shares Rise	Mar. 12	MT
Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell	Mar. 12	MT
Transcript : Regulus Therapeutics Inc. - Special Call	Mar. 12
Top Premarket Gainers	Mar. 12	MT
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity	Mar. 12	PR
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Mar. 12	PR
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in Its Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	Mar. 12	CI
Regulus Therapeutics Inc. announced that it expects to receive $100.000267 million in funding from a group of investors	Mar. 10	CI
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Jan. 02	PR
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease	Jan. 02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Regulus Therapeutics Inc Nasdaq

Equities

US75915K1016

Summary

Filters